Amino acid phosphoramidate nucleosides: potential ADEPT/GDEPT substrates

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Cancer Biology

Background:

• 5-fluoro-2 -deoxyuridine (FUdR) and 1-beta-arabinofuranosylcytosine (Ara-C) are established anticancer nucleoside analogs.
• Developing effective drug delivery systems for nucleoside analogs remains a challenge in cancer therapy.
• Prodrug strategies can enhance the stability, solubility, and cellular uptake of therapeutic agents.

Purpose of the Study:

• To synthesize and characterize novel amino acid phosphoramidate monoester prodrugs of FUdR and Ara-C.
• To evaluate the serum stability, water solubility, and nontoxicity of these novel prodrugs.
• To assess the efficacy of these prodrugs in inhibiting the growth of human leukemia cells in the presence of human prostatic acid phosphatase (hPAP).

Main Methods:

• Chemical synthesis of aromatic, serum-stable, water-soluble amino acid phosphoramidate monoesters.
• In vitro assays to determine serum stability, water solubility, and cytotoxicity.
• Cellular growth inhibition assays using the human leukemia cell line CCRF-CEM with hPAP.

Main Results:

• The synthesized amino acid phosphoramidate monoesters of FUdR and Ara-C exhibited favorable serum stability and water solubility.
• These novel prodrugs demonstrated low inherent toxicity.
• Significant inhibition of CCRF-CEM cell growth was observed in the presence of hPAP, indicating prodrug activation and efficacy.

Conclusions:

• Amino acid phosphoramidate monoester prodrugs of FUdR and Ara-C are promising candidates for leukemia therapy.
• The prodrug approach enhances the therapeutic potential of these nucleoside analogs.
• Further investigation into the in vivo efficacy and mechanisms of action is warranted.